Oct 22, 2026, 6:35 PMBiotechnology and Pharmaceuticals
Moderna Stock Tumbles on Reported Phase 3 Cancer Vaccine Leak
Moderna shares tumbled after a reported cancer-vaccine data leak, before Moderna and Merck present Phase 3 results at a medical conference this weekend.
Listen to this briefingAudio briefing
Summary
MarketWatch’s October 22, 2026 headline says Moderna’s stock tumbled after a reported leak involving data for an experimental cancer vaccine being developed with Merck. The available feed provides no leaked figures, stock-move percentage, efficacy or safety findings, trial details, or leak source, so the selloff cannot be assessed from the supplied text.
Moderna and Merck are expected to present the vaccine’s Phase 3 data this weekend at an unidentified medical conference. The presentation is the next disclosed event; the limited feed gives no exact date, session, or regulatory timeline.
Positives
- Phase 3 data exist for Moderna and Merck’s experimental cancer vaccine, marking a late-stage clinical readout.
- Moderna and Merck are expected to share the results publicly at a medical conference this weekend.
- The weekend schedule provides a defined near-term point for fuller information than the available feed contains.
Risks & concerns
- Moderna’s stock tumbled after the reported leak, according to MarketWatch’s headline, although the decline was not quantified.
- The reported leak preceded Moderna and Merck’s planned medical-conference presentation of the Phase 3 data.
- The feed discloses no efficacy, safety, statistical, conference, leak-source, or regulatory details, preventing substantive assessment of the results.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/modernas-stock-tumbles-after-reported-leak-of-data-for-cancer-vaccine-dcc897c1?mod=mw_rss_topstories
Read full article
